WebNDC HCPCS Product NDC: 68001-0283 Brand Name: Cisplatin Generic Name: Cisplatin Dosage Form Name: Injection Administration Route: Intravenous Substances: Name: Cisplatin Strength: 1.0 Unit: mg/mL Packages: Code: 68001-0283-27 Description: 1 VIAL in 1 CARTON (68001-283-27) / 50 mL in 1 VIAL (68001-283-24) Effective Date: Aug. 2, … WebApr 15, 2015 · CanMED: NDC. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies. ... Name: Cisplatin Strength: 1.0 Unit: mg/mL Packages: Code: 44567-0511-01 Description: 1 VIAL, MULTI-DOSE in 1 ...
16729-0288 Cisplatin - CanMED: NDC - SEER
WebFeb 1, 2024 · The molecular formula for Vincristine Sulfate, USP is C 46 H 56 N 4 O 10 ∙H 2 SO 4. It has a molecular weight of 923.04. The structural formula is as follows: Vincristine Sulfate, USP is a white to off–white powder. It is soluble in methanol, freely soluble in water, but only slightly soluble in 95% ethanol. WebMar 22, 2024 · Use of cisplatin therapy is associated with reduced total body clearance. In children, elevated serum SGPT levels are associated with reduced drug total body clearance. Prior use of cisplatin may also … solidworks pdm icon
44567-0511 Cisplatin - CanMED: NDC - SEER
WebAug 1, 2024 · Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Alimta ® is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. WebApr 3, 2024 · §Overall = 0 to 120 hours post-initiation of cisplatin chemotherapy. ... NDC 31722-165-31 1 vial per carton. Storage Fosaprepitant for injection vials must be refrigerated, store at 2°C to 8°C (36°F to 46°F). The reconstituted final drug solution is stable for 24 hours at ambient room temperature [at or below 25°C (77°F)]. ... WebApr 21, 2024 · A randomized controlled trial compared six cycles of cyclophosphamide 1000 mg/m 2, and cisplatin 100 mg/m 2 with or without Amifostine for Injection pretreatment at 910 mg/m 2, in two successive cohorts of 121 patients with advanced ovarian cancer. solidworks pdm manual